Search clinical trials for: Hormone Receptor Positive Breast Cancer

Total 147280 results

M.D. Anderson Cancer Center

Not yet recruiting

Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

Hormone Receptor-positive Human Epidermal Growth Factor 2-negative | Metastatic Invasive LObular Carcinoma

United States
Mayo Clinic

Recruiting

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients

Metastatic Breast Cancer | HER2-negative Breast Cancer | Hormone-receptor-positive Breast Cancer

United States
MedSIR
Stemline Therapeutics, Inc.

Not yet recruiting

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. (ADELA)

Advanced Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | ESR1 Gene Mutation
AstraZeneca

Not yet recruiting

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (EvoPAR-BR01)

Advanced Breast Cancer

Canada
Washington University School of Medicine
United States Department of Defense; Aclaris Therapeutics, Inc.

Not yet recruiting

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer

United States
Puma Biotechnology, Inc.

Not yet recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer (ALISCA-Breast1)

Metastatic Breast Cancer | Recurrent Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer

United States
Universitaire Ziekenhuizen KU Leuven
Eli Lilly and Company; Kom Op Tegen Kanker; Teva Pharma

Recruiting

Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer (ABBICAR)

Triple Negative Breast Neoplasms

Belgium
Medical College of Wisconsin

Not yet recruiting

Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer

Breast Cancer

United States
University of Chicago

Not yet recruiting

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Breast Cancer | HER2-positive Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

United States
Li Huiping

Not yet recruiting

A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer

Advanced Breast Cancer
Helwan University

Not yet recruiting

Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients. (Palbociclib)

Metastatic Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Hormone-receptor-positive Breast Cancer
NiKang Therapeutics, Inc.

Recruiting

A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

Small Cell Lung Carcinoma | Gastric Cancer | Ovarian Neoplasms | Ovarian Cancer | Solid Tumor | Endometrial Neoplasms | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Advanced Solid Tumor | Endometrial Cancer | Small-cell Lung Cancer | Platinum-resistant Ovarian Cancer | Ovarian Carcinoma | Solid... and other conditions

United States
Reshma L. Mahtani, D.O.
Gilead Sciences

Not yet recruiting

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC (SERIES)

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Hormone-receptor-positive Breast Cancer | Human Epidermal Growth Factor 2 Low Breast Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Not yet recruiting

Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | Estrogen Receptor-Positive Breast Carcinoma

United States
BeiGene

Recruiting

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Breast Cancer | Small Cell Lung Cancer | Gastric Cancer | Ovarian Cancer | Prostate Cancer | Advanced Solid Tumor | Endometrial Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer | Hormone-receptor-positive Breast Cancer

United States, Australia
BeiGene

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Breast Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Hormone Receptor Positive Malignant Neoplasm of Breast | HER2-negative Breast Cancer | Hormone-receptor-positive Breast Cancer

China
Laura Huppert, MD, BA
Ambrx, Inc.

Not yet recruiting

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Triple Negative Breast Cancer | Hormone Receptor Positive Breast Carcinoma | HER2 Low Breast Carcinoma | Hormone-receptor-positive Breast Cancer

United States
German Breast Group
GlaxoSmithKline; Stemline Therapeutics, Inc.

Not yet recruiting

Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer (ELEMENT)

BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | Hormone Receptor Positive HER-2 Negative Breast Cancer | Advanced or Metastatic Breast Cancer

Germany
National Cancer Institute (NCI)

Not yet recruiting

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Estrogen Receptor-Positive Breast Carcinoma

United States
University of Washington
Breast Cancer Research Foundation

Not yet recruiting

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic HER2-Negative Breast Carcinoma | Metastatic Hormone Receptor-Positive Breast Carcinoma | Locally Advanced Unresectable HER2-Negative Breast Carcinoma | Locally Advanced Unresectable Hormone Receptor-Positive...

United States
Nanjing Chia-tai Tianqing Pharmaceutical

Recruiting

A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer

HR Positive/HER-2 Negative Breast Cancer

China
Cliniques universitaires Saint-Luc- Université...
Jules Bordet Institute

Recruiting

A Study of the Gut Microbiome in Hormone Receptor-positive HER2-negative Breast Cancer Treated With CDK4/6 Inhibitors (CICLIBIOME)

Breast Cancer

Belgium
Jules Bordet Institute
KU Leuven; University of Milan

Not yet recruiting

Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt) (KePreSt)

Early-stage Breast Cancer | Estrogen-receptor-positive Breast Cancer

Belgium
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Neoadjuvant Pyrotinib Versus Placebo Combined With Chemotherapy in HR-positive and HER2-low Early Breast Cancer

Early-stage Breast Cancer | Breast Cancer Invasive | HER2 Low Breast Carcinoma | Hormone-receptor-positive Breast Cancer

China
Mridula George, MD

Recruiting

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

Breast Cancer

United States
Chongqing Precision Biotech Co., Ltd
First Affiliated Hospital of Wannan Medical College

Recruiting

Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors

Breast Cancer | Gastric Cancer | Lung Cancer | Rectal Cancer | Cholangiocarcinoma | Colon Cancer | Pancreas Cancer | Esophagus Cancer

China
University of Miami
National Cancer Institute (NCI)

Not yet recruiting

Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer (FastER)

Advanced Breast Cancer | HER2-positive Breast Cancer

United States
BeiGene

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Advanced Breast Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Non-small Cell Lung Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer | Hormone-receptor-positive...

Australia, United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Mobile Health for Adherence in Breast Cancer Patients

Breast Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Hormone Receptor-Positive Breast Carcinoma | HER2-Negative Breast Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC

Recruiting

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Metastatic Breast Cancer

United States
Mayo Clinic

Recruiting

Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage 0 Breast Cancer AJCC v8 | Hormone Receptor-Positive Breast Carcinoma

United States
Medical College of Wisconsin

Not yet recruiting

Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer

Breast Cancer

United States
RemeGen Co., Ltd.

Not yet recruiting

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Breast Neoplasms

China
Pfizer

Recruiting

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Advanced or Metastatic Breast Cancer

United States, Taiwan, China, Japan, Canada, Israel, Korea, Republic of, Argentina, Australia, Brazil
Memorial Sloan Kettering Cancer Center
Astellas Pharma US, Inc.; Corcept Therapeutics; Breast Cancer Research Foundation

Recruiting

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

Metastatic Breast Cancer

United States
Hoffmann-La Roche

Recruiting

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Belgium, Korea, Republic of, United States, Canada, China, Italy, France, Brazil, Australia, Argentina, Hong Kong, Portugal, Spain, Taiwan, Costa Rica, Israel, Thailand, Germany, New Zealand, Poland, Chile, Colombia, Guatemala, Hungary, Indi...
National Cancer Institute (NCI)

Recruiting

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Hormone Receptor-Positive Breast Carcinoma | HER2-Negative Breast Carcinoma

United States
Hongmei Zheng

Recruiting

The Benefits of Continued Use of Ovarian Function Suppression After 5 Years

Endocrine Therapy | Breast Cancer Female

China
Chongqing Precision Biotech Co., Ltd
Zhejiang University

Recruiting

A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors

Breast Cancer | Gastric Cancer | Colorectal Cancer | Bile Duct Cancer | Non-small Cell Lung Cancer | Pancreas Cancer | Esophagus Cancer

China
DualityBio Inc.
BioNTech SE

Recruiting

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

Metastatic Breast Cancer

United States, China, Australia
Olema Pharmaceuticals, Inc.

Recruiting

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01)

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | HER2 Negative Breast Carcinoma | ER Positive Breast Cancer

United States, Korea, Republic of, Australia, Taiwan, Hong Kong, Malaysia, Thailand, Argentina, Belgium, Portugal, Italy
Chongqing Precision Biotech Co., Ltd
Shanxi Bethune Hospital

Recruiting

CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors

Breast Cancer | Gastric Cancer | Esophageal Cancer | Lung Cancer | Rectal Cancer | Colon Cancer | Pancreas Cancer

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Patients With Low Risk, Hormone Responsive Breast Cancer

Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage 0 Breast Cancer AJCC v8 | HER2-Negative Breast Carcinoma | Estrogen Receptor-Positive Breast Carcinoma

United States
SOLTI Breast Cancer Research Group

Recruiting

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer (SOLTI-2104)

Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Premenopausal Breast Cancer

Spain
Memorial Sloan Kettering Cancer Center
AstraZeneca; Novartis Pharmaceuticals

Recruiting

A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer

Breast Cancer

United States
Carrick Therapeutics Limited
Pfizer

Recruiting

A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants (SUMIT-BC)

Breast Cancer | Metastatic Breast Cancer | Locally Advanced Breast Cancer

Spain, United States, Turkey, Hungary
Daiichi Sankyo, Inc.
AstraZeneca

Recruiting

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Breast Cancer

United States
University of Minnesota

Recruiting

A Feasibility Study of Topical Cannabinoids for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in Adults With Hormone Receptor-Positive Breast Cancer (CanAroma)

Musculoskeletal Syndrome

United States
Pfizer

Not yet recruiting

A Study to Learn About the Relationship Between Hepatic Impairment and Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal-bow-sai-klib)

Breast Cancer
Pfizer
Arvinas Estrogen Receptor, Inc.

Recruiting

A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer (VERITAC-3)

Breast Cancer

United States, China, Spain, Hungary, Japan, Australia, Brazil, Italy, Slovakia, Switzerland

Search clinical trials for: Hormone Receptor Positive Breast Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations